EDITORIAL NOTE ON TREATMENTOF CANCER THROUGH RADIOPHARMACEUTICALS

Abstract

Satya Lakshmi

Radio-drugs (RPs) are one of those decade old 'innovations of things to come' that never truly made it into the standard. The innovation is for the most part strong and natural, compelling and very much endured yet in addition saw as lumbering and excessively mind boggling. The procurement of Advanced Accelerator Applications by Novartis for $3.9B emphatically proposes that the time has come to look again—will RPs see a renaissance or land on the junkyard of flopped once encouraging advances?